Medical News today (Aug. 28) reports that the US Food and Drug Administration (FDA) has approved a vaccine that blocks a virus that causes microcephi, a birth defect.
It also will protect against other viruses, including dengue, the mosquito-borne disease that causes a global epidemic.
The agency announced the decision in a press release.
The agency also noted that the vaccine is the first approved for use against a virus known as Zika in the United States.
It is likely that the first vaccine will be administered in the US in September.
The new vaccine is a single-dose, four-interleaved, three-interleave vaccine.
The vaccine will initially be administered to children aged 6 months to 4 years and adults aged 18 years and older, the agency said.
It was also announced that the agency will release additional information on its Zika vaccine in the coming weeks.
In late May, the FDA approved the first Zika vaccine, a three-dose combination vaccine, to protect infants against the virus.
The new vaccine also blocks dengoe virus.
A single-virus vaccine has been the subject of multiple studies and clinical trials.
But the latest studies indicate that the combined vaccine is less effective than a single dose.